Cervarix regulatory update

The EC approved an MAA from GSK for Cervarix human papillomavirus (HPV) vaccine to prevent precancerous lesions and cervical cancer caused by HPV types 16 and 18. The vaccine formulated with adjuvant AS04 is approved in Australia and is under review in the U.S., where GSK expects FDA action in January 2008. ...